Efficacy, tolerability, and safety of erenumab for the preventive treatment of persistent post-traumatic headache attributed to mild traumatic brain injury: an open-label study-Reference-Cited by-同舟云学术

Efficacy, tolerability, and safety of erenumab for the preventive treatment of persistent post-traumatic headache attributed to mild traumatic brain injury: an open-label study

Published:2020-06-03 Issue:1 Volume:21 Page:
ISSN:1129-2369
Container-title:The Journal of Headache and Pain
language:en
Short-container-title:J Headache Pain

Author:

Ashina Håkan,Iljazi Afrim,Al-Khazali Haidar Muhsen,Eigenbrodt Anna Kristina,Larsen Eigil Lindekilde,Andersen Amalie Middelboe,Hansen Kevin John,Bräuner Karoline Bendix,Mørch-Jessen Thomas,Chaudhry Basit,Antic Sonja,Christensen Casper Emil,Ashina Messoud,Amin Faisal Mohammad,Schytz Henrik Winther

Funder

Novartis Healthcare A/S

Publisher

Springer Science and Business Media LLC

Subject

Anesthesiology and Pain Medicine,Clinical Neurology,General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s10194-020-01136-z.pdf

Reference21 articles.

1. Nampiaparampil DE (2008) Prevalence of chronic pain after traumatic brain injury: a systematic review. JAMA 300(6):711–719

2. van der Naalt J, Timmerman ME, de Koning ME, van der Horn HJ, Scheenen ME, Jacobs B et al (2017) Early predictors of outcome after mild traumatic brain injury (UPFRONT): an observational cohort study. Lancet Neurol 16(7):532–540

3. Rasmussen BK, Olesen J (1992) Symptomatic and nonsymptomatic headaches in a general population. Neurology 42(6):1225–1231